SCHEMBL10279840

SCHEMBL10279840

Bc1ccnc2c1CCN2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.37
KDR P35968 3/20 0.32
ASIC3 Q9UHC3 1/20 0.32
CHEK1 O14757 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
JAK2 O60674 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
ABL1 P00519 1/20 0.32
LCK P06239 1/20 0.32
RET P07949 1/20 0.32
MET P08581 1/20 0.32
PDGFRB P09619 1/20 0.32
PIM1 P11309 1/20 0.32
FGFR1 P11362 1/20 0.32
PDGFRA P16234 1/20 0.32
PRKACA P17612 1/20 0.32
FLT1 P17948 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150102 0.75 NOTUM (0.47) NNMTKDRLRRK2DRD1NOTUM
SCHEMBL13138806 0.75 PARP1 (0.42) NNMTKDRCHEK1AURKADAPK3
SCHEMBL13991574 0.75 PARP10 (0.42) NNMTDRD1NOTUMGRM5
SCHEMBL795352 0.75 NNMT (0.44) NNMTKDRDRD1
SCHEMBL580706 0.75 NNMT (0.37) NNMTDRD1NOTUMGRM5
SCHEMBL24288319 0.72 NNMT (0.38) NNMTDAPK3MAP4K4PIM1CSNK1A1
SCHEMBL14510804 0.72 HTR2A (0.35) NNMTPIM1PRKACAROCK1LRRK2
SCHEMBL11987587 0.71 HTR2C (0.43) NNMTDRD1NOTUM
SCHEMBL22685856 0.71 NNMT (0.41) NNMTDRD1
SCHEMBL21323893 0.71 HTR2A (0.43) NNMTDRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178533-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-05-15 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 NNMT 1744/4885KDR 1909/4885ASIC3 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.